Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icosabutate QT/QTc interval study in healthy subjects
NCT03577275Phase 1Completed
- Sponsor
- NorthSea Therapeutics
- Start
- Jun 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of icosabutate in dyslipidemia (4 arms), sponsored by NorthSea Therapeutics. Primary endpoint: Fridericia's Correction for QT Interval at 24 hours. Started Jun 2018; status: completed.
02
Drugs
icosabutate
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT03577275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03577275.